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Strength is a heritable trait with unknown polygenic nature. So far, more than 200 DNA 
polymorphisms associated with strength/power phenotypes have been identified majorly 
involving non-athletic populations. The aim of the present study was to investigate individually 
and in combination the association of 217 DNA polymorphisms previously identified as markers 
for strength/power phenotypes with elite strength athlete status. A case-control study involved 83 
Russian professional strength athletes (53 weightlifters, 30 powerlifters), 209 Russian and 503 
European controls. Genotyping was conducted using micro-array analysis. Twenty-eight DNA 
polymorphisms (located near or in ABHD17C, ACTG1, ADCY3, ADPGK, ANGPT2, ARPP21, 
BCDIN3D, CRTAC1, DHODH, GBE1, IGF1, IL6, ITPR1, KIF1B, LRPPRC, MMS22L, MTHFR, 
NPIPB6, PHACTR1, PLEKHB1, PPARG, PPARGC1A, R3HDM1, RASGRF1, RMC1, SLC39A8, 
TFAP2D, ZKSCAN5 genes) were identified to have an association with strength athlete status. 
Next, to assess the combined impact of all 28 DNA polymorphisms, all athletes were classified 
according to the number of ‘strength’ alleles they possessed. All highly elite strength athletes 
were carriers of at least 22 (up to 34) ‘strength’ alleles, while 27.8% of Russian controls had less 
than 22 ‘strength’ alleles (P<0.0001). The proportion of subjects with a high (≥26) number of 
‘strength’ alleles was significantly greater in highly elite strength athletes (84.8%) compared to 
less successful strength athletes (64.9%; OR=3.0, P=0.042), Russian (26.3%; OR=15.6, 
P<0.0001) or European (37.8%; OR=6.4, P<0.0001) controls. This is the first study to 
demonstrate that the likelihood of becoming an elite strength athlete depends on the carriage of a 
high number of strength-related alleles.  
 




It has long been established that skeletal muscle hypertrophy, hyperplasia, predominance of fast-
twitch muscle fibers, improved neurological adaptation and high glycolytic capacity are major 
contributing factors to the performance of strength/power athletes (9, 10, 33). Furthermore, 
strength athletes display completely different transcriptomic, biochemical, anthropometric, 
physiological, biomechanical and other characteristics compared to endurance athletes or non-
athletic cohorts (3, 11, 30, 31). These differences can be explained both by environmental 
(training, nutrition, etc.) and genetic factors. Indeed, studies indicate that there is a strong 
heritability of power and strength-related traits with genetic factors accounting for 30-85% of the 
variation in isometric, isotonic and isokinetic strength, jumping ability, and other muscle 
strength phenotypes (28, 40).  
Muscle strength/power phenotypes are accepted to be polygenic in nature – that is, 
multiple genetic factors influence the observed phenotype (20). For example, a polygenic profile 
(composed of variations of ACE, ACTN3, AGT, GDF8, IL6, and NOS3 genes) was able to 
distinguish elite power athletes (Spanish jumpers, sprinters) from both endurance athletes and a 
nonathletic population (29). Power athletes (sprinters, speed-strength (i.e. jumpers, throwers etc.) 
and strength athletes (i.e. weightlifters and powerlifters)) demonstrate the highest level of these 
phenotypes of any population. A recent review provided evidence that at least 69 genetic 
markers are linked to elite power athlete status (23). Of those, 11 DNA polymorphisms (AGT 
rs699, ACTN3 rs1815739, CKM rs8111989, CNTFR rs41274853, GBF1 rs2273555, HIF1A 
rs11549465, MLN rs12055409, MTHFR rs1801131, PPARG rs1801282, PPARGC1A rs8192678 
and ZNF608 rs4626333) have been shown to be associated with strength athlete status or 
strength performance in athletes (2, 5, 8, 12, 13, 14, 19, 27, 39). These genes are implicated in 
skeletal muscle contraction (ACTN3), growth and development (AGT, MLN, ZNF608), 
glycolysis (HIF1A), metabolism (GBF1, MTHFR, PPARG, PPARGC1A), energy homeostasis 
(CKM), and neurogenesis (CNTFR). 
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As for the studies involving non-athletic cohorts, using a genome-wide association study 
(GWAS) approach, 196 DNA polymorphisms were associated with handgrip strength in three 
large GWASs. Specifically, the study conducted by Willems et al. of 195,180 white Europeans 
identified 16 single nucleotide polymorphisms (SNPs) near or within the genes involved in 
muscle structure and function, and associated them with handgrip strength (36). Matteini and co-
workers examined associations of about 2.7 million SNPs in the GWAS with additional meta-
analysis of individuals over 65 years old and reported 41 variants to be linked with handgrip 
strength (24). A more recent meta-analysis study by Tikkanen et al. (32) identified 139 loci 
associated with handgrip strength in a UK Biobank cohort. Interestingly, Tikkanen et al. (32) 
also observed a significant positive relationship between genes highly expressed in brain and 
genetic associations for grip strength. They also observed the most significant enrichment of 
differentially expressed genes in muscle with high proportion of genes implicated in the 
regulation of skeletal muscle contraction. Overall, studies involving power athletes and untrained 
subjects indicate that carriers of gene variants associated with increased muscle mass, high 
proportion of fast-twitch muscle fibers, improved anaerobic metabolism and neurological 
adaptation have greater strength potential and better chances to compete at the highest level.  
One might hypothesize that multiple alleles associated with better power performance 
should be over-represented in elite strength athletes (weightlifters and powerlifters) compared to 
controls, thus playing some role in the selection of elite strength athletes. To date, no studies 
have attempted to quantify the impact of more than three genetic variants on elite strength 
performance / strength athlete status. The aim of the present study therefore was to investigate, 
individually and in combination, the association of 217 DNA polymorphisms previously 
identified as strength/power related phenotypes (195 SNPs associated with handgrip strength and 






Experimental Approach to the Problem 
To identify genetic markers associated with strength in 83 elite Russian strength athletes, we 
performed a case-control study using 217 SNPs previously discovered in non-athletic and 
athletic cohorts. Next, to assess the combined impact of all significant DNA polymorphisms, all 
athletes and controls were classified according to the number of ‘strength’ alleles they possessed. 
We then compared the proportion of subjects with a high number of ‘strength’ alleles between 
highly elite strength athletes, less successful strength athletes and controls. 
 
Subjects 
The study involved 83 strength athletes (53 weightlifters, 30 powerlifters; 54 men, 29 women). 
None of these athletes had ever tested positive for doping by a WADA-accredited laboratory. 
There were 46 athletes classified as ‘highly elite’ (ranked in the top 10 internationally; of those 
36 were weightlifters) and 37 athletes classified as ‘elite’ (participants in international 
competitions, all national team members). Age, height and body mass of athletes are presented in 
Table 1. Controls were 209 healthy unrelated Russians (166 men and 43 women; 45.1±4.4 yr) 
without any competitive sport experience (explored by survey). The athletes and controls were 
all Caucasians. In addition, data of European controls (n=503) were used from the 1000 
Genomes database for comparison with Russian athletes. 
 
Table 1 near here 
 
The overall study was approved by the Ethics Committee of the Physiological Section of 
the Russian National Committee for Biological Ethics. Written informed consent was obtained 
from each participant. The study complied with the guidelines set out in the Declaration of 
Helsinki and ethical standards in sport and exercise science research. The experimental 
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procedures were conducted in accordance with the set of guiding principles for reporting the 
results of genetic association studies defined by the Strengthening the Reporting of Genetic 
Association studies (STREGA) Statement.  
 
Procedures 
Molecular genetic analysis in all Russian athletes and controls was performed with DNA 
samples obtained from leukocytes (venous blood), as previously described (26). Briefly, 4 ml of 
venous blood was collected in tubes containing EDTA (Vacuette EDTA tubes, Greiner Bio-One, 
Austria). DNA extraction and purification were performed using a commercial kit according to 
the manufacturer's instructions (Technoclon, Russia). HumanOmni1-Quad BeadChips (Illumina 
Inc, USA) cover 1,140,419 SNPs including 217 of the 265 previously associated with relevant 
phenotypes in the literature (196 with handgrip strength, 69 with power athlete status), and were 
used for genotyping and subsequent imputation of the 217 available SNPs in athletes and 
controls (Supplemental Digital Content 1, contains information regarding all 217 SNPs). The 
assay required 200 ng of DNA sample with a concentration of at least 50 ng/µl.  
 
Statistical Analyses 
Statistical analyses were conducted using PLINK v1.90, R (version 3.4.3), and GraphPad InStat 
(GraphPad Software, Inc., USA) software. Haplotype phasing before imputation was performed 
using SHAPEIT. Imputation was performed using IMPUTE2. For phasing and imputation, we 
used 1000 Genomes Phase 3 data as a reference panel and imputed the variants with a frequency 
higher than 0.1% in the reference panel. Variants imputed with low certainty (info score < 0.6) 
were filtered out after imputation. All SNPs that did not pass the Hardy-Weinberg equilibrium 
test were excluded from further analysis. All data are presented as mean (standard deviation). 
Genotype distribution and allele frequencies between athletes (and subgroups of athletes) and 





Of the 217 SNPs, 28 (ABHD17C rs7165759 A, ACTG1 rs6565586 A, ADCY3 rs10203386 T, 
ADPGK rs4776614 C, ANGPT2 rs890022 A, ARPP21 rs1513475 C, BCDIN3D rs12367809 C, 
CRTAC1 rs563296 G, DHODH rs12599952 A, GBE1 rs9877408 A, IGF1 rs35767 A, IL6 
rs1800795 G, ITPR1 rs901850 T, KIF1B rs11121542 G, LRPPRC rs10186876 A, MMS22L 
rs9320823 T, MTHFR rs1801131 G, NPIPB6 rs2726036 A, PHACTR1 rs6905419 C, PLEKHB1 
rs7128512 G, PPARG rs1801282 G, PPARGC1A rs8192678 A, R3HDM1 rs6759321 T, 
RASGRF1 rs1521624 A, RMC1 rs303760 C, SLC39A8 rs13135092 A, TFAP2D rs56068671 T, 
ZKSCAN5 rs3843540 C) were nominally (P<0.05) associated with strength athlete status using 
different models (additive, recessive or dominant) either in all strength athletes (n=83) and / or 
subgroups of athletes (i.e. weightlifters (n=53), powerlifters (n=30), highly elite strength athletes 
(n=46), highly elite weightlifters (n=36)) (Table 2). More details for each SNP are shown in 
Supplemental Digital Content 1. Although no association passed Bonferroni correction for 
multiple testing (i.e. P value = 0.05/217 SNPs * 5 groups * 3 models (additive, recessive, 
dominant) = 0.000015), we felt justified to use 28 SNPs in the polygenic analysis given that we 
used SNPs already discovered independently, most via GWASs at genome-wide significance. 
 
Table 2 near here 
 
Next, to assess the combined impact of all 28 DNA polymorphisms, athletes and controls 
were classified according to the number of ‘strength’ alleles they possessed. All highly elite 
strength athletes were carriers of at least 22 (up to 34) ‘strength’ alleles, while 27.8% of Russian 
(OR=35.9, P<0.0001) and 17.9% of European (OR=20.4, P=0.0017) controls had less than 22 
‘strength’ alleles. The proportion of subjects with a high (≥26) number of ‘strength’ alleles was 
significantly greater in highly elite strength athletes (84.8%) compared to less successful (elite) 
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strength athletes (64.9%; OR=3.0, P=0.042), Russian (26.3%; OR=15.6, P<0.0001) or European 
(37.8%; OR=6.4, P<0.0001) controls (Figure 1). Furthermore, elite athletes also had greater 
proportion of subjects (64.9%) with a high (≥26) number of ‘strength’ alleles compared to 
Russian (26.3%; OR=5.2, P<0.0001) or European (37.8%; OR=3.0, P=0.0011) controls. 
 
Figure 1 near here 
 
DISCUSSION 
To our knowledge, this is the first comprehensive study aimed to identify polygenic profile of 
strength athletes using more than three gene polymorphisms. To genotype and impute multiple 
DNA variants associated with power performance we used a micro-array analysis to identify 28 
SNPs associated with elite strength athlete status in Russians. These SNPs are located in or near 
genes that have multiple functions including growth and development (ANGPT2, CRTAC1, 
IGF1, IL6, NPIPB6, R3HDM1, TFAP2D), metabolism (ABHD17C, ADCY3, ADPGK, 
BCDIN3D, DHODH, GBE1, ITPR1, LRPPRC, MTHFR, PPARG, PPARGC1A, RMC1, 
ZKSCAN5), cell motility (ACTG1, PHACTR1), neurogenesis (ARPP21, PLEKHB1, RASGRF1), 
DNA repair (MMS22L) and intracellular transport (KIF1B, SLC39A8). More details of gene 
functions are presented in Supplemental Digital Content 1. Interestingly, of those 28 genes, 16 
genes (ACTG1, ADCY3, ANGPT2, BCDIN3D, CRTAC1, GBE1, IGF1, KIF1B, LRPPRC, 
MMS22L, MTHFR, PHACTR1, PPARGC1A, R3HDM1, RASGRF1, ZKSCAN5) alter their 
expression in human skeletal muscle during adaptation to resistance training compared to pre-
training and/or non-exercise and endurance training states (34). More details of gene expression 
during resistance training are shown in Supplemental Digital Content 1. 
According to the GTEx portal, 22 SNPs (ABHD17C rs7165759, ACTG1 rs6565586, 
ADCY3 rs10203386, ADPGK rs4776614, ARPP21 rs1513475, BCDIN3D rs12367809, CRTAC1 
rs563296, DHODH rs12599952, GBE1 rs9877408, IL6 rs1800795, KIF1B rs11121542, LRPPRC 
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rs10186876, MTHFR rs1801131, NPIPB6 rs2726036, PHACTR1 rs6905419, PLEKHB1 
rs7128512, PPARG rs1801282, R3HDM1 rs6759321, RMC1 rs303760, SLC39A8 rs13135092, 
TFAP2D rs56068671, ZKSCAN5 rs3843540) are functional and influence expression of genes in 
various tissues, including skeletal muscle, nerves, blood and thyroid tissue – all important in 
terms of physical performance and training adaptations. More details of gene function are 
provided in Supplemental Digital Content 1. 
Next, using a panel of 28 SNPs, we identified that strength athletes possess at least 22 
‘strength’ alleles, while 27.8% of Russian and 17.9% of European controls had less than 22 
‘strength’ alleles. On the other hand, we found that most highly elite strength athletes were 
carriers of at least 26 ‘strength’ alleles. In the Russian and European populations there are only 
26.3% and 37.8% of people with such a polygenic profile compared to 84.8% in highly elite 
strength athletes.  
To date, the concept that strength performance is likely to be determined by the 
simultaneous presence of many advantageous genetic variants has only been addressed in 
principle (20) or in a mixed cohort of speed-strength athletes (15, 17, 29): few studies have yet 
sought to define or quantify the impact of multiple (i.e. more than two) genotype combinations 
that influence strength performance / strength athlete status and none have attempted this for 
more than three genetic variants (1, 5, 13, 14). We have thus addressed this issue, in a study 
focused on 217 DNA polymorphisms associated with strength/power phenotypes.  
Our study does have limitations. First, extension to, and replication within groups of 
differing geographic ancestry is needed to translate these findings more broadly (18, 25, 38). In 
general, less than 50% of findings can be replicated in subsequent studies. Indeed, we could 
confirm the association of just three SNPs (MTHFR rs1801131, PPARG rs1801282, PPARGC1A 
rs8192678) out of 11 previously associated with strength athlete status. However, besides case-
control studies, genotype-phenotype studies should be performed to identify genetic markers for 
physical performance (1, 4, 6, 16, 19, 21). Second, none of the associations passed correction for 
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multiple testing, but we felt justified to use 28 SNPs in the polygenic analysis given that we used 
SNPs already associated with relevant phenotypes in this validation phase. Of those 28 SNPs, 23 
were initially found in GWASs, meaning that in the discovery phase (the original articles) these 
SNPs have passed correction for multiple testing at genome-wide significance (P < 5.0·10-8). 
The other 5 SNPs were derived from previous candidate gene studies and associated in at least 
two previous independent cohorts of athletes. It is common not to adjust for multiple 
comparisons in the validation phase to prevent the loss of potentially important findings (7, 37). 
Third, the lack of functional data relating to 28 DNA polymorphisms needs to be addressed with 
further transcriptomic, histological and physiological studies. Further, the association of 
polygenic profile with alterations in muscle function in response to training is advocated. In 
addition, our study is limited to 217 common polymorphisms which were primarily selected 
because of previously reported associations with various aspects of strength performance. We 
strongly suspect that many additional common polymorphisms, and probably rare mutations as 
well, will be shown to be associated with strength performance in due course. Thus, we suspect 
that the 28 polymorphisms we have used constitute only a small fraction of the genetic factors 
that influence human muscle strength. However, looking to the future, when hundreds or 
thousands of polymorphisms will be discovered that contribute to the variability in human 
muscle strength, the power of such information as a practical tool for sports coaches will emerge.  
Although these 28 polymorphisms have been associated with high levels of achievement in 
strength sports, we still believe that this is not of sufficient influence to be used in the selection 
of athletes (35). Currently, ‘performance tests’ (such as vertical jump, isometric mid-thigh pull 
and weightlifting performance) or traditional laboratory tests (such as isokinetic dynamometry 
and handgrip strength) are used to help identify young athletes with appropriate physiological 
potential, and to guide them into suitable training and competition. Such tests may, in the future, 
be augmented by assessment of polygenic profile. 
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In conclusion, our findings confirm the polygenic nature of elite strength performance, a 
classic complex trait, and demonstrate that the likelihood of becoming an elite strength athlete 
depends on the number of strength-related alleles an individual possesses. 
 
PRACTICAL APPLICATIONS 
Our results highlight the relationship between a genetic profile derived from 28 polymorphisms 
and elite competitive strength performance. While many more genetic factors undoubtedly 
remain undiscovered, these 28 provide a basis on which future, more comprehensive, genetic 
assessments might augment systems of identifying and nurturing talent in elite strength sports. 
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Figure 1. The combined impact of the 28 DNA polymorphisms. The percentage of subjects with 
a high (≥ 26) number of ‘strength’ alleles is shown. *The proportion of subjects with a high 
number of ‘strength’ alleles was significantly greater in highly elite strength athletes (84.8%) 



















Males n = 31 n = 23 
Age (years) 23.7±0.7 28.0±0.9 
Height (cm) 179.0±1.6 174.5±2.2 
Body mass (kg) 96.7±3.7 82.3±4.9 
   
Females n = 22 n = 7 
Age (years) 22.5±0.8 25.0±0.7 
Height (cm) 165.1±1.8 160.7±2.6 














Table 2. Associations between strength alleles identified in previous studies (in the same 
direction of association) and strength athlete status in the Russian groups of athletes and 
controls. 
Strength allele Group of athletes 
Frequency of the 
strength allele, % P* 
Athletes Controls 
BCDIN3D rs12367809 C 
All strength athletes 61.4 
50.0 
0.018 
Weightlifters 61.5 0.037 
SLC39A8 rs13135092 A All strength athletes 97.5 93.0 0.043 
RASGRF1 rs1521624 A 
All strength athletes 53.8 
42.6 
0.019 
Weightlifters 52.9 0.044 
Highly elite strength athletes 54.4 0.047 
CRTAC1 rs563296 G All strength athletes 55.1 45.6 0.048 
R3HDM1 rs6759321 T 
All strength athletes 66.4 
49.5 
0.001 
Weightlifters 68.5 0.001 
Highly elite strength athletes 63.8 0.026 
Highly elite weightlifters 71.0 0.002 
ARPP21 rs1513475 C Highly elite strength athletes 31.5 23.7 0.039 
ADCY3 rs10203386 T Highly elite strength athletes 62.0 54.5 0.043 
PHACTR1 rs6905419 C Highly elite strength athletes 85.6 72.4 0.01 
MMS22L rs9320823 T 
Highly elite strength athletes 43.3 
30.3 
0.025 
Highly elite weightlifters 44.3 0.027 
C18orf8 rs303760 C Highly elite strength athletes 74.4 65.1 0.021 
PPARG rs1801282 G 
Highly elite strength athletes 26.1 
15.6 
0.022 
All strength athletes 20.5 0.045 
TFAP2D rs56068671 T Weightlifters 10.8 4.6 0.03 
PLEKHB1 rs7128512 G Weightlifters 95.3 88.7 0.046 
GBE1 rs9877408 A Weightlifters 69.8 61.2 0.027 




All strength athletes 63.6 0.009 
Highly elite strength athletes 64.4 0.0268 
Highly elite weightlifters 70.0 0.0042 
MTHFR rs1801131 G Weightlifters 36.5 23.1 0.0079 
21 
 
All strength athletes 34.1 0.008 
Highly elite weightlifters 37.5 0.012 
LRPPRC rs10186876 A 
Highly elite weightlifters 54.2 
33.9 
0.001 
All strength athletes 45.5 0.014 
Weightlifters 45.3 0.04 
Highly elite strength athletes 50.0 0.006 
DHODH rs12599952 A Highly elite weightlifters 44.4 31.3 0.041 
NPIPB6 rs2726036 A Highly elite weightlifters 68.6 56.4 0.013 
ITPR1 rs901850 T 
Highly elite weightlifters 30.9 
18.4 
0.022 
Weightlifters 27.6 0.049 
Highly elite strength athletes 26.7 0.036 
ABHD17C rs7165759 A Powerlifters 36.2 22.7 0.034 




Highly elite strength athletes 39.8 0.047 
ACTG1 rs6565586 A Powerlifters 42.6 27.0 0.024 
ANGPT2 rs890022 A Powerlifters 15.0 6.3 0.03 
KIF1B rs11121542 G Powerlifters 95.0 87.2 0.04 
ZKSCAN5 rs3843540 C Powerlifters 22.4 13.2 0.04 
IGF1 rs35767 A Powerlifters 30.0 17.5 0.033 
PPARGC1A rs8192678 A Powerlifters 45.0 31.1 0.04 
 
*P<0.05, all differences between athletes and controls are statistically significant. More details 
are shown in Supplemental Digital Content 1).  
